Home Markets Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) pipeline Market Research Report...

Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) pipeline Market Research Report 2017

148
SHARE

Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) Development are “Aptose Biosciences Inc Arvinas Inc, AstraZeneca Plc, ConverGene LLC, Dybly AG, F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, GlaxoSmithKline Plc, Incyte Corp, Kainos Medicine Inc, Merck & Co Inc, Nuevolution AB, Plexxikon Inc, Resverlogix Corp, Trillium Therapeutics Inc

The Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) pipeline guide also reviews of key players involved in therapeutic development for Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.

Sample copy is available at https://www.marketinsightsreports.com/reports/062215759/bromodomain-containing-protein-4-protein-hunk1-or-brd4-pipeline-review-h1-2017/inquiry

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4). The pipeline guide reviews pipeline therapeutics for Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4).
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4). Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 Or BRD4) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report at: https://www.marketinsightsreports.com/reports/062215759/bromodomain-containing-protein-4-protein-hunk1-or-brd4-pipeline-review-h1-2017

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 – Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 21 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Breast Cancer, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Hematological Tumor, Inflammation, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atherosclerosis, Colorectal Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Alzheimer’s Disease, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Burkitt Lymphoma, Carcinomas, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Metastatic Liver Cancer, Nephropathy, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pre-Diabetes/Impaired Glucose Tolerance, Renal Cell Carcinoma, Retinal Degeneration, Rheumatoid Arthritis, Small-Cell Lung Cancer, Substance (Drug) Abuse and Systemic Lupus Erythematosus.

LEAVE A REPLY

Please enter your comment!
Please enter your name here